Analysts Offer Predictions for TWST Q2 Earnings

Twist Bioscience Co. (NASDAQ:TWST) – William Blair issued their Q2 2026 earnings per share estimates for Twist Bioscience in a research note issued on Tuesday, February 4th. William Blair analyst M. Larew expects that the company will post earnings per share of ($0.41) for the quarter. The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.27) per share.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The business’s revenue was up 24.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.75) EPS.

Several other equities analysts have also commented on the company. Leerink Partners upped their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Barclays lowered their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Scotiabank raised their target price on Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a research note on Tuesday. Wolfe Research started coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. Finally, Robert W. Baird increased their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus price target of $53.80.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $53.66 on Wednesday. Twist Bioscience has a 1 year low of $27.41 and a 1 year high of $60.90. The firm’s 50-day moving average is $48.74 and its 200-day moving average is $46.27. The company has a market cap of $3.19 billion, a P/E ratio of -14.91 and a beta of 1.87.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 1,347 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $64,656.00. Following the transaction, the senior vice president now owns 114,147 shares of the company’s stock, valued at approximately $5,479,056. This represents a 1.17 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $43.26, for a total value of $254,628.36. Following the sale, the chief financial officer now directly owns 110,096 shares of the company’s stock, valued at approximately $4,762,752.96. This represents a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 59,002 shares of company stock valued at $2,851,681. 3.01% of the stock is owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds have recently modified their holdings of the stock. Massachusetts Financial Services Co. MA raised its holdings in Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after buying an additional 20,035 shares during the period. Barclays PLC increased its position in shares of Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after acquiring an additional 104,420 shares in the last quarter. FMR LLC raised its holdings in shares of Twist Bioscience by 6.0% during the third quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after acquiring an additional 12,327 shares during the period. Avanza Fonder AB purchased a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $1,059,000. Finally, BNP Paribas Financial Markets boosted its stake in Twist Bioscience by 128.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock worth $1,718,000 after purchasing an additional 21,357 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.